Meta-analysis of CXCR7 Expression Related to Clinical Prognosis in Cancers

Qian Cheng¹, Yingfeng Wen², Zhirong Sun¹, Yanyan Zhang¹, Xiaoxiao Qian³, Jianguo Wu¹* and Dongsheng Xu²,5*

¹Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China
²Center for Neuroimmunology and Regenerative Therapy, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, P. R. China
³University of Nebraska Medical Center School of Medicine, Omaha, NE 68198, USA
⁴Department of Neurology, Shanghai Minhang District Central Hospital, Shanghai, 201199, P. R. China
⁵State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, P. R. China

Abstract

Purpose: Recently, higher expression of chemokine receptors in patients with various cancer types has been observed and indicated to have prognostic significance in the clinical progression of cancers. Former research has determined that CXCR7, as a member of chemokine receptor C-X-C family, empowers greater affinity with chemokine CXCL12 than CXCR4. The present study investigated the correlation of clinical characteristics and CXCR7 expression in cancers using meta-analysis.

Methods: A comprehensive search on PubMed and Web of Science identified CXCR7-related clinical studies. Methodological quality of these studies was evaluated and all the data were extracted, calculated, and analyzed. This meta-analysis was carried out with Stata 12.0.

Results: Fifteen eligible studies consisting of 1780 participants were included. The results showed that CXCR7 significantly relates to tumor occurrence (pooled RR=3.12, 95% CI: 1.71-5.70, P=0.000), tumor grades (pooled RR=1.41, 95% CI: 1.14-1.75, P=0.002), tumor stages (pooled RR=1.51, 95% CI: 1.26-1.82, P=0.000) and lymph node metastasis (pooled RR=1.49, 95% CI: 1.14-1.94, P=0.000), respectively.

Conclusion: Highly expressed chemokine receptor CXCR7 potentially increases tumor occurrence risk. Higher CXCR7 expression is associated with poorer prognosis, advanced stages, differentiation grades and poor lymph node metastasis in patients with various cancers. Thus, highly expressed CXCR7 could be a potential biomarker in the prognosis of cancers.

Keywords: CXCR7; Cancer; Tumor grade; Tumor stage; Lymph node metastasis; Meta-analysis

Introduction

Chemokines are a group of small molecular peptides that play predominant roles in inflammation and cancer biology. CXCL12 (or SDF-1), stromal-derived growth factor is one of the member of the chemokines, which are low-molecular-weight signaling peptides involved in cell homing and mobilization. The CXCL12-CXCR4/CXCR7 axis is believed to be a significant signal axis that contributes to tumor progression [1].

The chemokine receptor CXCR4, as a member of the four groups (CXC, CC, C, and D), is a 352-amino acid heptahelical transmembrane receptor. CXCR4 potentiates growth, angiogenesis/angiostasis, invasion/metastasis and prognosis of various cancers, including esophageal cancer, renal cancer, breast cancer, colorectal carcinoma, glioma, gastric cancer and ovarian cancer [1-8]. CXCR4 is significantly associated with tumor stage, lymph node status, distant metastasis and poor survival [1,3-6,8,9].

CXCR7 is a novel receptor of CXCL12, and is involved in the progression and metastasis in various cancers. There are literatures indicating that CXCR7 binds to CXCL12 with greater affinity than CXCR4 to CXCL12 (Kd = 0.4 nM versus 3.6 nM) [10,11]. Furthermore, the roles of CXCR7 in neovascularization, tumor invasion and proliferation have been verified [12-14]. On the other hand, the clinical pattern of CXCR7 in various cancers has not been thoroughly summarized, and controversy still exists in different researches. Zhen Liu et al. found no relationship between CXCR7 expression and histological grade, whereas Gebauer et al. found that CXCR7 expression had an association with grading in cancers [15,16].

Meta-analysis has great advantages in confirming clinical confounding outcome of disparate studies by using data and results of published articles. In this study, the meta-analysis aims to review and systematically assess the potential correlations of CXCR7 expression with the clinicopathological indicators in various cancers.

Materials and Methods

Search strategy

We carried out a comprehensive literature review on PubMed, Web of Science and Embase up to December 2014. We used the following terms: “CXCR7 or RDC1 or C-X-C chemokine receptor type 7”, and “carcinoma or cancer or tumor or neoplasm”. All references from retrieved articles were scanned to identify other potentially available reports.

*Corresponding authors: Dongsheng Xu, Center for Neuroimmunology and Regenerative Therapy, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, P. R. China, Tel: 402-559-3797, E-mail: dxu0927@sina.cn
Changhong Miao, Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, P. R. China, Tel: 402-559-3797, E-mail: miaochhi@aliyun.com

Received March 13, 2016; Accepted March 30, 2016; Published April 06, 2016

Citation: Cheng Q, Wen Y, Sun Z, Zhang Y, Qian X, et al. (2016) Meta-analysis of CXCR7 Expression Related to Clinical Prognosis in Cancers. J Integr Oncol 5: 163. doi:10.4172/2329-6771.1000163

Copyright: © 2016 Cheng Q, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Selection criteria

All eligible articles that indicated any associations between CXCR7 and clinicopathological indicators in various tumors were collected in this meta-analysis by two reviewers independently. The inclusion criteria that eligible studies had to meet were as follows: (1) CXCR7 expression evaluated in the primary tumor tissues, (2) researches revealed the association between CXCR7 expression and tumor clinicopathological indicators and prognosis, (3) CXCR7 expression examined by immunohistochemistry (IHC), reverse transcription PCR (RT-PCR), (4) articles published as a full paper in English, (5) for duplicate articles, only the most complete and/or recently published one was included. The exclusion criteria were as follows: (1) reviews, comments, case reports, conference abstracts, editorials, letters, and non-English language papers, (2) articles with insufficient or unavailable information of CXCR7 expression with clinicopathological parameters and prognosis.

Data extraction and quality assessment

The following information was retrieved independently by two authors (Qian Cheng and Zhirong Sun) from each publication: first author, publication year, country, number of patients enrolled, histology and disease stage.

Disagreements in data extraction were resolved by consensus and by referring back to the original article.

Quality assessment

Quality assessment was carried out by two independent investigators through reading and scoring each publication according to the quality scale for the biological prognostic factors.

Data analysis

Statistical analysis was conducted using Stata 12.0 (Stata Corporation, USA). To assess heterogeneity of studies, we used the I^2 test and Fixed-effects models (Mantel-Haenszel, I^2 < 50%). In the case when there was heterogeneity (Mantel-Haenszel, I^2 ≥ 50%) among studies, we performed a random effect model to pool the RRs; otherwise, a fixed effect model was selected.

Results

Identification of eligible studies

Initially, 407 articles were retrieved using the search strategy described above. 356 of which were excluded due to having irrelevant titles or abstracts, non-original articles or non-English language articles. Through further scrutinizing the entire paper, 36 articles were excluded for insufficient data. Finally, a total of 15 articles were applicable, and 1780 patients of various cancers were enrolled in the meta-analysis (Figure 1).

All the features of the 15 eligible studies with a total of 1780 patients were summarized in Table 1. Among them, two articles were from Germany, two from Italy, one from France, one from USA, and nine from China. The expression of CXCR7 was detected using immunohistochemistry in 12 studies, and the other three studies applied immunohistochemistry on a tissue microarray. Tumor tissues in this meta-analysis were taken from cancers in thyroid, cervical, colorectal, cutaneous, hepatocellular, esophageal, pancreatic, renal, gallbladder, mesothelioma and oral. The years of the studies range from 2010 to 2014, and antibodies used for CXCR7 detection were mainly from R&D and Abcam.

Correlation of CXCR7 expression with clinicopathological parameters

There were eight studies, with a total of 635 patients, included in the correlation analysis between CXCR7 expression and tumor occurrence. The results are shown in Figure 2A (RR=3.12, 95% CI: 1.71-5.70, P<0.001, I^2=84.2%), which indicate that CXCR7 expression was significantly higher in tumor tissue than in its relevant normal tissue.

There were eight studies, with a total of 348 patients, enrolled in the correlation analysis between CXCR7 expression and tumor grade. The results are shown in Figure 2B (RR=1.41, 95% CI: 1.14-1.75, P<0.01, I^2=41.6%), which indicate that CXCR7 expression was higher in tumor grade III and IV compared to grade I and II. We can interpret as CXCR7 expression correlates with worse tumor grade and prognosis potential.

There were nine studies, with a total of 1238 patients, involved in the correlation analysis between CXCR7 expression and tumor stage. The results are showed in Figure 2C (RR=1.51, 95% CI: 1.26-1.82, P<0.001, I^2=49.4%), which demonstrate that CXCR7 expression was...
significantly higher in tumor stage III and IV than in stage I and II. It is shown that CXCR7 expression correlates with worse tumor stage and prognosis potential.

There were ten studies, with a total of 995 patients, included in the correlation analysis between CXCR7 expression and lymph node metastasis. The results are revealed in Figure 2D (RR=1.49, 95% CI: 1.14-1.94, P<0.001, I^2=70.0%), which indicate that CXCR7 expression was significantly higher in metastatic lymph node compared to normal lymph node. We can state that CXCR7 expression predicts lymph node metastasis potential and poorer prognosis.

Publication bias

Neither Begg's nor Egger's tests indicated evidence of significant publication bias. In addition, no publication bias was observed in the funnel plot of enrolled studies (Figure 3).

Discussion

Chemokines play an important role in oncogenesis and tumor progression. CXCR7, as a recently discovered chemokine receptor, has demonstrated its characteristics in six aspects out of the ten top hallmarks of tumors, including resisting cell death, inducing angiogenesis, sustaining proliferative signaling, activating invasion and metastasis, tumor-promoting inflammation, and cancer-related genes [14,17-22]. Both CXCR4 and CXCR7 are receptors of chemokine CXCL12 and have been reported in multiple tumor types. However, the functions of highly expressed CXCR7 in tumor tissues are unclear. Past report has implied that CXCR7 may play a more critical role in pancreatic cancer progression and prognosis. Shen et al. regarded CXCR4 as a key receptor involved in tumor invasion and prognosis, while Liu et al. [9] considered CXCR7 to be more important for long term survival in pancreatic cancer patients [9,23,24]. Implications of CXCR7 have been revealed in various tumors, including nervous system, digestive system, endocrine system, genital system, blood system, respiratory system, and urinary system, respectively [9,15,25-29]. However, systemic study of the correlation of CXCR7 with clinicopathogy and prognosis in various tumors is still vacant. This study was initiated from the aspect of CXCR7 expression, and its correlation with tumor grade, tumor stage, and lymph node metastasis. In cervical cancer research [30], colorectal cancer research by Xu et al. [19] cutaneous squamous cell
carcinoma research by Hu et al. [21] renal cancer research by Wang et al. [26] and gallbladder cancer research by Yao et al. [27] all of these studies have consistent results for tumor grade, stage and lymph node metastasis [30-34]. These significant clinicopathological relative factors revealed their roles in tumor development [35-40]. This meta-analysis has drawn the distance between CXCR7 and the clinicopathological indicators closer. Furthermore, CXCR7 may become a valuable biomarker for tumor grade and stage discrimination, and prognosis evaluation through tissue biopsy for diagnosis and prognosis [41].

Acknowledgements

This research was supported in part by funds provided through the Hatch Act, the Layman Award and the Charles J Millard Trust Fund. This research was also supported by National Natural Science Foundation of China (81471936 and 81271420) and Major National Scientific Research Projects (2014CB965000).

Conflict of Interest

We declare that we have no conflict of interest.

References

1. Tang B, Tang F, Li Y, Yuan S, Li B, et al. (2015) Clinicopathological significance of CXCR4 expression in renal cell carcinoma: a meta-analysis. Ann Surg Oncol 22: 1026-1031.
2. Liu CF, Liu SY, Min XY’, Ji YY, Wang N, et al. (2014) The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. PLoS One 9: e92629.
3. Han M, Lv S, Zhang Y, Yi R, Huang B, et al. (2014) The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis. Tumour Biol 35: 4589-4597.
4. Lv S, Yang Y, Kwon S, Han M, Zhao F, et al. (2014) The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis. Histopathology 64: 701-712.
5. Wu J, Wu X, Liang W, Chen C, Zheng L, et al. (2014) Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis. Tumour Biol 35: 3709-3715.
6. Zhang Z, Ni C, Chen W, Wu P, Wang Z, et al. (2014) Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer 14: 49.
7. Zhu Q, Han X, Peng J, Qin H, Wang Y (2012) The role of CXC chemokines and their receptors in the progression and treatment of tumors. J Mol Histo l 43: 699-713.
8. Lv S, Sun B, Zhong X, Dai C, Wang W, et al. (2015) The Clinical Implications of Chemokine Receptor CXCR4 in Grade and Prognosis of Glioma Patients: A Meta-Analysis. Mol Neurobiol 52: 555-561.
9. Liu Z, Yang L, Teng X, Zhang H, Guan H (2014) The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma. J Surg Res 191: 379-388.
10. Crump MP, Gong JH, Loetscher P, Rajaratnam K, Amara A, et al. (1997) Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16: 6996-7007.
11. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, et al. (2005) The chemokine SDF-1/CXCL12 binds to CXCR4 through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 35760-35766.

12. Lin L, Han MM, Wang F, Xu LL, Yu HX, et al. (2014) CXCR7 stimulates MAPK signaling to regulate hepatocarcinoma cell progression. Cell Death Dis 5: e1488.

13. Jin J, Zhao W C, Yuan F (2013) CXCR7/CXCR4/CXCL12 axis regulates the proliferation, migration, survival and tube formation of choroid-retinal endothelial cells. Ophthalmic Res 50: 6-12.

14. Li XX, Zheng HT, Huang LY, Shi DB, Peng JJ, et al. (2014) Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal cancer through ERK and β-arrestin pathways. Int J Oncol 45: 1649-1657.

15. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, et al. (2011) Prognostic impact of CXCR4 expression in esophageal cancer. J Transl Med 11: 238.

16. Liu Z, Teng XY, Meng XP, Wang BS (2014) Expression of stromal cell-derived factor 1 and CXCR7 ligand receptor system in pancreatic adenocarcinoma. World J Surg Oncol 12: 348.

17. Liu Z, Sun DX, Teng XY, Xu WX, Meng XP, et al. (2012) Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma. Endocr Pathol 23: 247-253.

18. Kurban S, Tursun M, Kurban G, Hasim A (2014) Role of CXCR7 and effects on CXCL12 in SH4 cells and upregulation in cervical squamous cell carcinomas in Uighur women. Asian Pac J Cancer Prev 15: 9211-9216.

19. Xu H, Wu Q, Dang S, Jin M, Xu J, et al. (2011) Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One 6: e27399.

20. Guillomot E, Karimjee-Solliti B, Pradelli E, Benchetrit M, Goguet-Surmenian E, et al. (2012) CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br J Cancer 107: 1944-1949.

21. Hu SC, Yu HS, Yen FL, Chen GS, Lan CC (2014) CXCR7 expression correlates with tumor depth in cutaneous squamous cell carcinoma skin lesions and promotes tumor cell survival through ERK activation. Exp Dermatol 23: 902-908.

22. Neve PM, Ierano C, D’Alterio C, Simona LN, Napoli M, et al. (2015) CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. Cell Mol Immunol 12: 472-482.

23. Zheng K, Li HY, Su XL, Wang XY, Tian T, et al. (2010) Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 29: 31.

24. Tachezy M, Zander H, Gebauer F, von Loga K, Pantel K, et al. (2013) CXCR7 expression in esophageal cancer. J Transl Med 11: 238.

25. D’Alterio C, Consales C, Polimenio M, Franco R, Cindolo L, et al. (2010) Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets 10: 772-781.

26. Wang L, Chen W, Gao L, Yang Q, Liu B, et al. (2012) High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J Surg Oncol 10: 212.

27. Yao X, Zhou L, Han S, Chen Y (2011) High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J Int Med Res 39: 1253-1264.

28. Li T, Li H, Wang Y, Harvord C, Tan JL, et al. (2011) The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol 223: 519-530.

29. Xia J, Wang J, Chen N, Dai Y, Hong Y, et al. (2011) Expressions of CXCR7/ligands may be involved in oral carcinogenesis. J Mol Histol 42: 175-180.

30. Heckmann D, Maier P, Laufs S, Li L, Sleeman JP, et al. (2014) The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer. Clin Cancer Res 20: 604-616.

31. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.

32. Liu Y, Carson-Walter E, Walter KA (2015) Targeting chemokine receptor CXCR7 inhibits glioma cell proliferation and mobility. Anticancer Res 35: 53-64.

33. Miao Z, Luker KE, Summers BC, Bereshtyshiv R, Bhojani MS, et al. (2007) CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 104: 15735-15740.

34. Wani N, Nasser MW, Ahirwar DK, Zhao H, Miao Z, et al. (2014) C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res 16: R54.

35. Zhong W, Chen W, Zhang D, Sun J, Y L, et al. (2012) CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study. Exp Ther Med 4: 363-369.

36. Shen B, Zheng MQ, Lu JW, Jiang Q, Wang TH, et al. (2013) CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells. Asian Pac J Cancer Prev 14: 5403-5408.

37. Hao M, Zheng J, Hou K, Wang J, Chen X, et al. (2012) Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol 84: 204-214.

38. Calatzzolzo C, Canazza A, Pollo B, Di Pierro E, Ciusani E, et al. (2011) Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol Ther 11: 242-253.

39. Goguet-Surmenian E, Richard-Fiardo P, Guillomot E, Benchetrit M, Gomez-Brouchet A, et al. (2013) CXCR7-mediated progression of osteosarcoma in the lungs. Br J Cancer 109: 1579-1585.

40. Melo RCC, Longhini AL, Bigarella CL, Baratti MO, Traina F, et al. (2014) CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12. PLoS One 9: e86926.

41. Walentowicz-Sadlecka M, Sadlecki P, Bodnar M, Marszałek A, Walentowicz P, et al. (2014) Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients. PLoS One 9: e84629.